Clinical trial · Interventional
Olanzapine for Chemotherapy-induced Nausea and Vomiting Prophylaxis
Efficacy and Dosage of Olanzapine for Chemotherapy-induced Nausea and Vomiting Prophylaxis in Women With Gynecologic Cancers Receiving Carboplatin-based Regimen : a Double-blind, Placebo-controlled, Randomized Crossover Trial
NCT04232423CI-TRIAL-00056071OLN-EMEcompletedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To investigate that olanzapine can reduced side effect about nausea and vomiting in women with gynecologic cancers receiving carboplatin-based regimen by using olanzapine and placebo
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Complete Response Rate to Chemotherapy-induced Nausea and Vomiting Prophylaxis | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Olanzapine 10 Mg ORAL TABLET | Drug | — | UNRESOLVED |
| Olanzapine 5 Mg ORAL TABLET | Drug | — | UNRESOLVED |
| Placebo ORAL TABLET | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- OLN 0-5-10
- description
- Placebo tablet in chemotherapy cycle 1, olanzapine 5 mg tablet in chemotherapy cycle 2, and olanzapine 10 mg tablet in chemotherapy cycle 3
- interventionNames
- Drug: Olanzapine 10 Mg ORAL TABLET
- Drug: Olanzapine 5 Mg ORAL TABLET
- Drug: Placebo ORAL TABLET
- type
- EXPERIMENTAL
- label
- OLN 5-10-0
- description
- Olanzapine 5 mg tablet in chemotherapy cycle 1, olanzapine 10 mg tablet in chemotherapy cycle 2, and placebo tablet in chemotherapy cycle 3
- interventionNames
- Drug: Olanzapine 10 Mg ORAL TABLET
- Drug: Olanzapine 5 Mg ORAL TABLET
- Drug: Placebo ORAL TABLET
- type
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Women with gynecological cancer receiving carboplatin-based chemotherapeutic regimen * ECOG performance status 0-1 * Normal bone marrow, liver, and renal functions * Can speak and write in Thai language Exclusion Criteria: * Women with nausea or vomiting prior to chemotherapeutic administration * Pregnant women * Women with active infection * Women with bowel obstruction * Women with symptomatic brain metastases * Women who received dopamine receptor antagonists within 1 week before chemotherapeutic administration * Women who received corticosteroid within 1 week before chemotherapeutic administration * Women with past history of chemotherapy or radiotherapy * Women with psychiatric disorders * Women with poor controlled diabetes mellitus * Women who received anticonvulsant medication * Women with history of neuroleptic malignant syndrome * Women with history of olanzapine allergy * Women with history of lactose intolerance
References
Publications (0)
Data not yet available
No reference posted for this study.